Menu

Building the next generation of healthcare companies

Delivering transformational treatments to patients Register to listen to Syncona’s Interim Results Presentation on 21st November at 9.30am.

Who we are

Syncona is a leading healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

Investors

Syncona is a FTSE250 business listed on the London Stock Exchange. Find the latest share price, announcements, presentations and events here.

Our portfolio

A selective portfolio of high quality healthcare businesses in truly innovative areas of science

Learn more

Transformational treatments

As we seek to build companies in truly innovative areas in healthcare, our ultimate goal is to deliver transformational treatments to patients, enabling them to continue enjoying their lives

Learn more

Achilles Therapeutics and the advent of immunotherapy

Syncona speaks to Achilles Therapeutics' clinical founder Charlie Swanton about his career, the advent of immunotherapy, and what he wants Achilles to achieve.

Emma Salisbury - measuring the potential impact of gene therapy

Emma Salisbury, mother of Tommy Salisbury, tells us about the impact of Choroideremia and the potential of gene therapy.

Latest news

View all
Blue Earth Diagnostics Announces Results of Investigational Phase 3 Blinded Image Evaluation Study of 18F-Fluciclovine PET Imaging in Glioma
19.11.2018
View
Freeline appoints Brian M. Silver as Chief Financial Officer and Head of Corporate Development
14.11.2018
View
Gyroscope Therapeutics led consortium secures INNOVATE UK funding to develop a suspension platform for cost effective manufacture of novel AAV gene therapies
14.11.2018
View
Blue Earth Diagnostics Announces 18F-Fluciclovine Research Presentation at Upcoming Society for Neuro-Oncology (SNO) Annual Scientific Meeting
14.11.2018
View